IL-7 treatment does not skew the T-cell repertoire. Following T-cell–replete and TCD BMT, the Vβ repertoire was evaluated at day 70 for PBS-treated (▨, □) and IL-7–treated (▪, ▤) recipients. Percentages per Vβ type are expressed as percentage of all Vβ types per treatment modality.